Dacomitinib in the management of advanced non-small-cell lung cancer

SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - Springer
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …
被引用次数：44 相关文章

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - europepmc.org
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - search.proquest.com
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - infona.pl
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

S Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - search.ebscohost.com
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - pubmed.ncbi.nlm.nih.gov
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …